You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)

  • Technology appraisal
  • Reference number: TA206
  • Published:  27 October 2010
  • Guidance
  • Tools and resources
  • History

On this page

  1. Background information
  2. Lymphoma (non-Hodgkin's) - bendamustine: provisional matrix
  3. Lymphoma (non-Hodgkin's) - bendamustine: draft scope for consultation

History

A list of downloadable documents created during development.

Background information

  • Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal): press release information

  • 2010/153 NICE publishes guidance on three cancer drugs (PDF 73 KB)

    Published:
    06 December 2013

Lymphoma (non-Hodgkin's) - bendamustine: provisional matrix

  • Lymphoma (non-Hodgkin's) - bendamustine: provisional matrix (PDF 59 KB)

    Published:
    28 May 2010

Lymphoma (non-Hodgkin's) - bendamustine: draft scope for consultation

  • Lymphoma (non-Hodgkin's) - bendamustine: draft scope for consultation (PDF 76 KB)

    Published:
    28 May 2010